Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase...( - Lead Investigator Professor John F....),Health

- Lead Investigator Professor John F. Thompson Presented Results at The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies in New York City -

- Detailed Efficacy Data to be Presented at ASCO May 29-June 2, 2009 -

KNOXVILLE, Tenn., March 16 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the interim safety and efficacy results from the first 20 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma are as good as or better than Phase 1 data. Additionally, extended Phase 1 survival data was reported.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/pvct/37429/

The lead investigator for Provectus' Phase 2 study of PV-10 for metastatic melanoma, Professor John F Thompson, MD, presented the update on Provectus' development efforts at The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13, 2009 in New York City. A detailed analysis of the interim Phase 2 study results will be made available at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program on May 29 - June 2, 2009 in Orlando, Florida."

Commenting on extended long-term survival data now available for subjects who participated in the Phase 1 study, Thompson noted, "There was an improvement in survival for those subjects achieving an objective response of their injected lesions, with a mean survival of 34.8 months as of early March, compared with a mean survival of 29.7 months calculated in October 2008. These results are even more interesting when one looks at disease-specific survival, where the mean for the response-positive group has increased to 37.3 months. This indicates tha
'/>"/>